Industry incentives and antibiotic resistance: an introduction to the antibiotic susceptibility bonus.
Journal
The Journal of antibiotics
ISSN: 1881-1469
Titre abrégé: J Antibiot (Tokyo)
Pays: England
ID NLM: 0151115
Informations de publication
Date de publication:
07 2020
07 2020
Historique:
received:
17
02
2020
accepted:
22
02
2020
pubmed:
24
3
2020
medline:
29
12
2020
entrez:
24
3
2020
Statut:
ppublish
Résumé
The scarcity of novel antibiotic compounds in a time of increasing resistance rates has begun to ring alarm bells at the highest echelons of government. Large new financial incentives to accelerate antibiotic research and development, such as market entry rewards (MERs), are being considered. However, there is little focus on how to sustain the efficacy of new, promising antibiotics reaching the market. Currently, inappropriate use of antibiotics is commonplace, which has accelerated resistance development. In an attempt to halt this trend, antibiotic stewardship policies are being implemented in many resource-rich settings. Unfortunately, this has not yet had an impact on the amount of antibiotics being prescribed globally. One important hurdle is misalignment of incentives. While governments and health services are incentivized to promote prudent use of this common good, pharmaceutical companies are incentivized to increase volume of sales to maximize profits. This problem must be addressed or else the major efforts going into developing new antibiotics will be in vain. In this paper we outline an approach to realign the incentives of pharmaceutical companies with wider antibiotic conservation efforts by making a staged bonus a component of an MER for antibiotic developers when resistance to their drug remains low over time. This bonus could address the lack of stewardship focus in any innovation-geared incentive.
Identifiants
pubmed: 32203126
doi: 10.1038/s41429-020-0300-y
pii: 10.1038/s41429-020-0300-y
pmc: PMC7292800
doi:
Substances chimiques
Anti-Bacterial Agents
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
421-428Subventions
Organisme : CIHR
Pays : Canada
Références
World Bank. Drug resistant infections: a threat to our economic future (vol. 2): final report. 2017. Report Number 114679. http://documents.worldbank.org/curated/en/323311493396993758/pdf/114679-REVISED-v2-Drug-Resistant-Infections-Final-Report.pdf .
UK Review on Antimicrobial Resistance. (chaired by Jim O’Neill). Tackling drug-resistant infections globally: final report and recommendations. 2016. https://amr-review.org/Publications.html .
Simpkin VL, Renwick MJ, Kelly R, Mossialos E. Incentivising innovation in antibiotic drug discovery and development: progress, challenges and next steps. J Antibiot. 2017;70:1087. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5746591/#__ffn_sectitle .
doi: 10.1038/ja.2017.124
Mossialos E, Morel CM, Edwards SE, Berensen J, Gemmill-Toyama M, Brogen D. Policies and incentives for promoting innovation in antibiotic research. European Observatory on Health Systems and Policies. 2010. http://www.euro.who.int/__data/assets/pdf_file/0011/120143/E94241.pdf .
Morel CM, Mossialos E. Stoking the antibiotic pipeline. BMJ. 2010;340:1115–8. http://www.bmj.com/bmj/section-pdf/186569?path=/bmj/340/7756/Analysis.full.pdf .
doi: 10.1136/bmj.c2115
UK government. Tackling antimicrobial resistance 2019–2024, The UK’s five-year national action plan. 2019. https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/784894/UK_AMR_5_year_national_action_plan.pdf .
U.S. Congress. Re-Valuing Anti-Microbial Products Act of 2018. 2018. https://www.congress.gov/bill/115th-congress/house-bill/6294/text .
Infectious Disease Society of America. Testimony of the Infectious Diseases Society of America on U.S. Biodefense, Preparedness, and Implications of Antimicrobial Resistance for National Security, prepared for the U.S. House of Representatives Committee on Oversight and Reform Subcommittee on National Security. 2019. https://www.idsociety.org/globalassets/idsa/policy--advocacy/current_topics_and_issues/antimicrobial_resistance/10x20/statements/062619-idsa-testimony-re-antimicrobial-resistance-and-national-security.pdf .
Rex JH, Outterson K. Antibiotic reimbursement in a model delinked from sales: a benchmark-based worldwide approach. Lancet Inf Dis. 2016;16:500–5.
doi: 10.1016/S1473-3099(15)00500-9
European Commission. A European One Health Action Plan against antimicrobial resistance. 2018. https://ec.europa.eu/health/amr/sites/amr/files/amr_action_plan_2017_en.pdf .
Laxminarayan R, Duse A, Wattal C, et al. Antibiotic resistance—the need for global solutions. Lancet Infect Dis. 2013;13:1057–98.
doi: 10.1016/S1473-3099(13)70318-9
Holmes AH, Moore LSP, Sundsfjord A, et al. Understanding the mechanisms and drivers of antimicrobial resistance. Lancet. 2016;387:176–87.
doi: 10.1016/S0140-6736(15)00473-0
Schroeck JL, Ruh CA, Sellick JA Jr, et al. Factors associated with antibiotic misuse in outpatient treatment for upper respiratory tract infections. Antimicrob Agents Chemother. 2015;59:3848–52.
doi: 10.1128/AAC.00652-15
Dekker AR, Verheij TJ, van der Velden AW. Inappropriate antibiotic prescription for respiratory tract indications: most prominent in adult patients. Fam Pract. 2015;32:401–7.
pubmed: 25911505
Davey PG, Bax RP, Newey J, et al. Growth in the use of antibiotics in the community in England and Scotland in 1980-93. BMJ. 1996;312:613.
doi: 10.1136/bmj.312.7031.613
Wang EE, Einarson TR, Kellner JD, et al. Antibiotic prescribing for Canadian preschool children: evidence of overprescribing for viral respiratory infections. Clin Infect Dis. 1999;29:155–60.
doi: 10.1086/520145
Davey P, Marwick CA, Scott CL, et al. Interventions to improve antibiotic prescribing practices for hospital inpatients. Cochrane Database Syst Rev. 2017;2:CD003543. https://doi.org/10.1002/14651858.CD003543.pub4 .
Llor C, Bjerrum L. Antimicrobial resistance: risk associated with antibiotic overuse and initiatives to reduce the problem. Ther Adv Drug Saf. 2014;5.6:229–41.
doi: 10.1177/2042098614554919
Huttner B, Harbarth S, Nathwani D, et al. Success stories of implementation of antimicrobial stewardship: a narrative review. Clin Microbiol Infect. 2014;20:954–62.
doi: 10.1111/1469-0691.12803
Eurosurveillance. WHO member states adopt global action plan on antimicrobial resistance. 2015. https://www.eurosurveillance.org/content/10.2807/ese.20.21.21137-en .
WHO. Library of national action plans. 2019. http://www.who.int/antimicrobial-resistance/national-action-plans/library/en .
Klein EY, Van Boeckel TP, et al. Global increase and geographic convergence in antibiotic consumption between 2000 and 2015. Proc Natl Acad Sci USA. 2018. https://doi.org/10.1073/pnas.1717295115 .
National Institute of Health, National U.S. National Library of Medicine, ClinicalTrials.gov. 2019. https://clinicaltrials.gov/ct2/results?cond=&term=telithromycin&cntry=&state=&city=&dist= .
U.S. Department of Justice. Novartis Vaccines & Diagnostics to pay more than $72 million to resolve False Claims Act allegations concerning TOBI. 2019. https://www.justice.gov/opa/pr/novartis-vaccines-diagnostics-pay-more-72-million-resolve-false-claims-act-allegations .
WHO. WHO guidelines on use of medically important antimicrobials in food-producing animals. 2019. https://www.who.int/foodsafety/areas_work/antimicrobial-resistance/cia_guidelines/en/ .
Stewardson AJ, Huttner B, Harbarth S. At least it won’t hurt: the personal risks of antibiotic exposure. Curr Opin Pharmacol. 2011;11:446–52.
doi: 10.1016/j.coph.2011.06.011
Renwick MJ, Brogan DM, Mossialos E. A systematic review and critical assessment of incentive strategies for discovery and development of novel antibiotics. J Antibiot. 2015;69:73–88.
doi: 10.1038/ja.2015.98
DRIVE-AB Consortium. Report: revitalizing the antibiotic pipeline stimulating innovation while driving sustainable use and global access. 2018. http://drive-ab.eu/wp-content/uploads/2018/01/CHHJ5467-Drive-AB-Main-Report-180319-WEB.pdf .
Kesselheim A, Outterson K. Improving antibiotic markets for long-term sustainability. Yale J Health Policy Law Ethics 2011;11:101–67.
pubmed: 21381513
Kesselheim A, Outterson K. Fighting antibiotic resistance: marrying new financial incentives to meeting public health goals. Health Aff 2010;29:1689–96.
doi: 10.1377/hlthaff.2009.0439
Outterson K, Pogge T, Hollis A. Combating antibiotic resistance through the Health Impact Fund. In: Cohen G, editor. The globalization of health care: legal and ethical issues. Oxford: Oxford University Press. 2013.
FDA. Guidance for industry postmarketing studies and clinical trials—implementation of Section 505(o)(3) of the Federal Food, Drug, and Cosmetic Act. 2011. https://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM172001.pdf .
Cavaleri M. EMA activities in the fight against AMR Human medicines aspects. European Medicines Agency. 2017. http://www.ema.europa.eu/docs/en_GB/document_library/Presentation/2017/10/WC500236309.pdf .
Rex JH, Talbot GH, Goldberger MJ, et al. Progress in the fight against multidrug-resistant bacteria 2005–2016: modern noninferiority trial designs enable antibiotic development in advance of epidemic bacterial resistance. Clin Infect Dis. 2017;65:141–6.
doi: 10.1093/cid/cix246